204 related articles for article (PubMed ID: 35978379)
21. Lenalidomide and Dexamethasone for a Patient of POEMS Syndrome Presenting with Massive Ascites.
Ueda S; Yonemoto S; Oka K; Fujii N; Nakata K; Matsunaga H; Kataoka S; Iwama Y; Narahara H; Yasunaga Y; Inui Y; Kawata S
Case Rep Hematol; 2014; 2014():818946. PubMed ID: 24782932
[TBL] [Abstract][Full Text] [Related]
22. [Successful treatment of myelomatous pleural effusion with daratumumab administration before autologous peripheral stem cell transplantation].
Wada A; Yasumura S; Kajikawa S; Murakami J; Sato T
Rinsho Ketsueki; 2020; 61(8):879-884. PubMed ID: 32908050
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
24. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
25. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
26. First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS).
Sevindik OG; Mutlu YG; Aydin BB; Serin I
Hemasphere; 2022 Jul; 6(7):e728. PubMed ID: 35747589
[No Abstract] [Full Text] [Related]
27. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
30. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Popat U; Saliba R; Thandi R; Hosing C; Qazilbash M; Anderlini P; Shpall E; McMannis J; Körbling M; Alousi A; Andersson B; Nieto Y; Kebriaei P; Khouri I; de Lima M; Weber D; Thomas S; Wang M; Jones R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2009 Jun; 15(6):718-23. PubMed ID: 19450756
[TBL] [Abstract][Full Text] [Related]
31. POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Ordway S; Gilbert L; Wanko S
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30054320
[TBL] [Abstract][Full Text] [Related]
32. Ischemic Stroke in a Patient With Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, and Skin Changes Syndrome Treated With Lenalidomide.
Sodavarapu S; Mahajan A
Cureus; 2020 Jul; 12(7):e9346. PubMed ID: 32850219
[TBL] [Abstract][Full Text] [Related]
33. Leave It to the Prose: A Case of POEMS Syndrome.
Samant S; Umpierrez De Reguerro A
Cureus; 2021 Oct; 13(10):e18664. PubMed ID: 34790444
[TBL] [Abstract][Full Text] [Related]
34. Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation.
Imai N; Taguchi J; Yagi N; Konishi T; Serizawa M; Kobari M
Neuromuscul Disord; 2009 May; 19(5):363-5. PubMed ID: 19269178
[TBL] [Abstract][Full Text] [Related]
35. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
36. POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Plasma Cell Disorder, and Skin Changes) Syndrome as a Sequela of Castleman Disease: A Case Report.
Haider SA; Iram S; Rashid AA; Manazar A; Javed H
Cureus; 2023 Nov; 15(11):e49330. PubMed ID: 38143657
[TBL] [Abstract][Full Text] [Related]
37. Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma.
Agarwal R; Abidi MH
Hematol Rep; 2012 Nov; 4(4):e26. PubMed ID: 23355944
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of a patient with POEMS syndrome by tandem high-dose chemotherapy with autologous CD34+ purged stem cell rescue.
Kojima H; Katsuoka Y; Katsura Y; Suzuki S; Suzukawa K; Hasegawa Y; Nagasawa T
Int J Hematol; 2006 Aug; 84(2):182-5. PubMed ID: 16926143
[TBL] [Abstract][Full Text] [Related]
39. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma.
Yoshihara S; Yoshihara K; Shimizu Y; Imado T; Takatsuka H; Kawamoto H; Misawa M; Ifuku H; Ohe Y; Okada M; Fujimori Y
Hematology; 2021 Dec; 26(1):388-392. PubMed ID: 34000225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
